[go: up one dir, main page]

ES2421641T3 - Procedimiento para la preparación de valsartan - Google Patents

Procedimiento para la preparación de valsartan

Info

Publication number
ES2421641T3
ES2421641T3 ES08750212T ES08750212T ES2421641T3 ES 2421641 T3 ES2421641 T3 ES 2421641T3 ES 08750212 T ES08750212 T ES 08750212T ES 08750212 T ES08750212 T ES 08750212T ES 2421641 T3 ES2421641 T3 ES 2421641T3
Authority
ES
Spain
Prior art keywords
valsartan
formula
compound
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08750212T
Other languages
English (en)
Inventor
Gomez Antonio Cosme
Nicolau Francisco Eugenio Palomo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Iberica SA
Original Assignee
Chemo Iberica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Iberica SA filed Critical Chemo Iberica SA
Application granted granted Critical
Publication of ES2421641T3 publication Critical patent/ES2421641T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)

Abstract

Procedimiento para preparar valsartán caracterizado porque comprende hacer reaccionar un compuesto defórmula general (I): **Fórmula** donde R es un grupo protector seleccionado del grupo que consiste en 1-metil-1-feniletilo, trifenilmetilo y t-butilo, conácido sulfúrico concentrado para obtener el compuesto de fórmula (II): **Fórmula** a continuación, hidrogenar catalíticamente el compuesto (II) en presencia de una base orgánica, y aislar valsartán ouna de sus sales farmacéuticamente aceptables.
ES08750212T 2007-05-14 2008-05-08 Procedimiento para la preparación de valsartan Active ES2421641T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200701365A ES2316281B1 (es) 2007-05-14 2007-05-14 Procedimiento para la preparacion de valsartan.
PCT/EP2008/055719 WO2008138871A1 (en) 2007-05-14 2008-05-08 Process for the preparation of valsartan

Publications (1)

Publication Number Publication Date
ES2421641T3 true ES2421641T3 (es) 2013-09-04

Family

ID=39580295

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200701365A Expired - Fee Related ES2316281B1 (es) 2007-05-14 2007-05-14 Procedimiento para la preparacion de valsartan.
ES08750212T Active ES2421641T3 (es) 2007-05-14 2008-05-08 Procedimiento para la preparación de valsartan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES200701365A Expired - Fee Related ES2316281B1 (es) 2007-05-14 2007-05-14 Procedimiento para la preparacion de valsartan.

Country Status (3)

Country Link
EP (1) EP2160384B1 (es)
ES (2) ES2316281B1 (es)
WO (1) WO2008138871A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR082435A1 (es) * 2010-08-03 2012-12-05 Novartis Ag Valsartan altamente cristalino
CN102702118B (zh) * 2012-06-11 2014-04-16 吉林三善恩科技开发有限公司 一种缬沙坦有机药物共晶及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
EP1812411A2 (en) * 2005-07-05 2007-08-01 Teva Pharmaceutical Industries Ltd. Process for preparing valsartan

Also Published As

Publication number Publication date
EP2160384B1 (en) 2013-04-17
EP2160384A1 (en) 2010-03-10
ES2316281B1 (es) 2010-02-09
ES2316281A1 (es) 2009-04-01
WO2008138871A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
AR076027A1 (es) Metodos e intermediarios para la preparacion de agentes farmaceuticos
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
CL2013002617A1 (es) Proceso para preparar una composicion de inhibidores de jak(pirrolo(2,3-d)pirimidin-4-il)pirazolil-3-ciclopentilpropanonitrilo tratando un exceso enantiometrico r o s mediante una reaccion de epimerizacion en presencia de base o una retro adicion de michael.
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
ECSP12011968A (es) Nuevos compuestos tricíclicos
CU20110052A7 (es) Compuestos orgánicos
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
UY32049A (es) Inhibidores de cmet
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
BR112015005862A2 (pt) derivados de hidropirrolpirrol para uso como inibidores de ácido graxo sintase
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
AR074845A1 (es) Procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
MX2017000926A (es) Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble.
AR072143A1 (es) Procedimiento para la preparacion de un producto intermedio para la sintesis de etexilato de dabigatran
UA107784C2 (en) Inhibitor of melanin production
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
AR075915A1 (es) Proceso para la obtencion de derivados de acido propionico
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
CO6321288A2 (es) Sales de compuestos inhibidores de vih
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
AR107494A1 (es) Proceso para la preparación de osimertinib (azd9291) o una sal del mismo, y “azd9291 anilina” o una sal de la misma